Pharma Equity Group A/S
The Board of Directors' resolution on the issuance of convertible loans
The Board of Directors' resolution on the issuance of convertible loans
| The Board of Directors' resolution on the issuance of convertible loans | |
| April 1, 2025 Announcement no. 4 The Board of Directors of Pharma Equity Group has decided to issue convertible loans in accordance with the authorisation in the Company's Articles of Association under item 4.3.A. The convertible loans allow Pharma Equity Group to borrow up to DKK 6,757,895. The main terms and conditions for the convertible loans are:
Upon conversion of the loans into new shares, the new shares will be issued without pre-emptive rights for the company's existing shareholders and with the same rights as the company's existing shares. The new shares will therefore be admitted to trading on Nasdaq Copenhagen. The conversion will take place at a price corresponding to an amount of DKK 0.20 being converted into one new share in the Company with a nominal value of DKK 0.10. The maximum increase of the share capital as a result of the conversion of the convertible loans is nominally DKK 7,577,666. The remaining terms of the convertible loans will be set out in the terms and conditions of the bonds, and the Board of Directors' decision on the issuance of the convertible loan will be incorporated into the Company's Articles of Association. The company's updated articles of association will be posted on the website. Of the convertible loans issued by the Board of Directors as of the date of this company announcement, DKK 6,757,895 has been subscribed for and paid to the Company. For further information, please contact: | |
| Christian Tange, CEO of Pharma Equity Group A/S, phone: +45 2948 8417 Christian Vinding Thomsen, Chairman of the Board of Directors of Pharma Equity Group A/S, phone: +45 2622 7222 |
About Pharma Equity Group A/S
Pharma Equity Group is a listed company on Nasdaq Copenhagen's main list. The company's main focus is on promoting the various drug candidates in its subsidiary, Reponex Pharmaceuticals A/S. With an unwavering focus on Health Care, Pharma Equity Group's primary goal is to add significant value to Reponex Pharmaceuticals' various drug candidates.
The Company is committed to providing comprehensive support, resources, and expertise to drive the development and success of these drug candidates. As a strategic partner, the Pharma Equity Group works closely with Reponex Pharmaceuticals and prioritizes the promotion of innovative medical solutions and cutting-edge treatments. Only when the full potential of Reponex Pharmaceuticals has been unfolded is the intention to explore opportunities to invest in other companies. This approach ensures a strong commitment to the current medical projects and their development, while remaining – in the longer term – open to new strategic investments for continued growth.
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
ALK Abello3.4.2025 16:23:51 CEST | Press release
Grant of share-based long-term incentive instruments to members of the Board of Management and key employees
ALK Abello3.4.2025 16:23:51 CEST | Pressemeddelelse
Tildeling af aktiebaserede langsigtede incitamentsinstrumenter til direktion og ledende medarbejdere
Statkraft AS3.4.2025 16:06:16 CEST | Press release
Statkraft AS signs loan agreement with NIB
James Wellbeloved3.4.2025 16:01:06 CEST | Press release
Eight in ten dog lovers take as much care over choosing their pet’s dinner as they do with their own meals, new research has revealed
Brunel International NV3.4.2025 16:00:00 CEST | Press release
GENERAL MEETING OF SHAREHOLDERS BRUNEL INTERNATIONAL N.V.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom